PT1305314E - Agente terapeutico cristalino - Google Patents

Agente terapeutico cristalino

Info

Publication number
PT1305314E
PT1305314E PT01951842T PT01951842T PT1305314E PT 1305314 E PT1305314 E PT 1305314E PT 01951842 T PT01951842 T PT 01951842T PT 01951842 T PT01951842 T PT 01951842T PT 1305314 E PT1305314 E PT 1305314E
Authority
PT
Portugal
Prior art keywords
crystal
therapeutic agent
therapeutic
agent
crystal therapeutic
Prior art date
Application number
PT01951842T
Other languages
English (en)
Inventor
Albert Shaw Wood
Richard Anthony Storey
Harris Laurence James
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PT1305314E publication Critical patent/PT1305314E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
PT01951842T 2000-07-28 2001-07-18 Agente terapeutico cristalino PT1305314E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
PT1305314E true PT1305314E (pt) 2005-04-29

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01951842T PT1305314E (pt) 2000-07-28 2001-07-18 Agente terapeutico cristalino

Country Status (46)

Country Link
EP (1) EP1305314B1 (pt)
JP (1) JP2004505087A (pt)
KR (1) KR100457937B1 (pt)
CN (1) CN1207297C (pt)
AP (1) AP1400A (pt)
AR (1) AR032628A1 (pt)
AT (1) ATE286901T1 (pt)
AU (2) AU7269001A (pt)
BG (1) BG107266A (pt)
BR (1) BR0112734A (pt)
CA (1) CA2417264C (pt)
CZ (1) CZ2003126A3 (pt)
DE (1) DE60108398T2 (pt)
DO (1) DOP2001000217A (pt)
DZ (1) DZ3364A1 (pt)
EA (1) EA004681B1 (pt)
EC (1) ECSP034454A (pt)
EE (1) EE200300045A (pt)
ES (1) ES2231521T3 (pt)
GE (1) GEP20053494B (pt)
HK (1) HK1055954A1 (pt)
HR (1) HRP20030061A2 (pt)
HU (1) HUP0302982A3 (pt)
IL (1) IL153226A0 (pt)
IN (1) IN2002MU01649A (pt)
IS (1) IS6626A (pt)
MA (1) MA26931A1 (pt)
MX (1) MX233602B (pt)
MY (1) MY117831A (pt)
NO (1) NO324220B1 (pt)
NZ (1) NZ523226A (pt)
OA (1) OA12337A (pt)
PA (1) PA8523501A1 (pt)
PE (1) PE20020277A1 (pt)
PH (1) PH12001001922B1 (pt)
PL (1) PL365133A1 (pt)
PT (1) PT1305314E (pt)
SK (1) SK572003A3 (pt)
SV (1) SV2001000570A (pt)
TN (1) TNSN01112A1 (pt)
TW (1) TWI285643B (pt)
UA (1) UA72631C2 (pt)
UY (1) UY26854A1 (pt)
WO (1) WO2002010171A1 (pt)
YU (1) YU4703A (pt)
ZA (1) ZA200301457B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
AU2004234158B2 (en) 2003-04-29 2010-01-28 Pfizer Inc. 5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
JP2007532526A (ja) 2004-04-07 2007-11-15 ファイザー・インク ピラゾロ[4,3−d]ピリミジン類
WO2006120552A2 (en) * 2005-05-12 2006-11-16 Pfizer Inc. ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1134442C (zh) * 1998-04-20 2004-01-14 美国辉瑞有限公司 吡唑并嘧啶酮cGMP PDE5抑制剂、其制备方法及用途及中间体
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
GEP20053494B (en) 2005-04-25
IS6626A (is) 2002-11-18
HRP20030061A2 (en) 2003-04-30
NO20030416D0 (no) 2003-01-27
ES2231521T3 (es) 2005-05-16
CZ2003126A3 (cs) 2004-02-18
DE60108398D1 (de) 2005-02-17
IL153226A0 (en) 2003-07-06
EP1305314B1 (en) 2005-01-12
ECSP034454A (es) 2003-03-10
HUP0302982A3 (en) 2005-01-28
AR032628A1 (es) 2003-11-19
BG107266A (bg) 2003-07-31
IN2002MU01649A (pt) 2004-12-11
NO20030416L (no) 2003-02-05
EP1305314A1 (en) 2003-05-02
EA200300079A1 (ru) 2003-06-26
DE60108398T2 (de) 2005-12-22
TWI285643B (en) 2007-08-21
ZA200301457B (en) 2004-04-28
MX233602B (es) 2006-01-10
PH12001001922B1 (en) 2006-11-21
KR20030016430A (ko) 2003-02-26
WO2002010171A1 (en) 2002-02-07
KR100457937B1 (ko) 2004-11-20
JP2004505087A (ja) 2004-02-19
MXPA03000856A (es) 2003-06-06
UA72631C2 (uk) 2005-03-15
YU4703A (sh) 2006-01-16
CN1207297C (zh) 2005-06-22
HK1055954A1 (en) 2004-01-30
PA8523501A1 (es) 2002-10-24
AU2001272690B2 (en) 2005-12-08
EA004681B1 (ru) 2004-06-24
SV2001000570A (es) 2002-09-03
ATE286901T1 (de) 2005-01-15
NZ523226A (en) 2003-07-25
EE200300045A (et) 2004-12-15
UY26854A1 (es) 2002-02-28
NO324220B1 (no) 2007-09-10
PE20020277A1 (es) 2002-05-11
HUP0302982A2 (hu) 2003-12-29
CA2417264C (en) 2007-06-12
AP2001002234A0 (en) 2001-09-30
CN1444585A (zh) 2003-09-24
BR0112734A (pt) 2004-08-10
MY117831A (en) 2004-08-30
DZ3364A1 (fr) 2002-02-07
PL365133A1 (en) 2004-12-27
MA26931A1 (fr) 2004-12-20
CA2417264A1 (en) 2002-02-07
AP1400A (en) 2005-04-28
SK572003A3 (en) 2004-05-04
OA12337A (en) 2006-05-15
DOP2001000217A (es) 2002-10-30
TNSN01112A1 (fr) 2005-11-10
AU7269001A (en) 2002-02-13

Similar Documents

Publication Publication Date Title
DK1637127T3 (da) Terapeutisk mikroskum
NO20025580D0 (no) Medisinsk anordning
DE69924365D1 (de) Massagegerät
ID30590A (id) Celana sekali pakai jenis-celana pendek
NO20014490L (no) Medisinske blandinger
NO20022692L (no) Terapeutiske midler
DE60130237D1 (de) Lasertherapiegerät
NO20032122L (no) Forbedret behandling
DE50209245D1 (de) Neuroprotektives medikament
PT1227724E (pt) Agente herbicida
DE60032946D1 (de) Katheter
DE60009451D1 (de) Massagegerät
DE60222664D1 (de) Hautbehandlungsmittel
DE10196460T1 (de) Selbstzerstör-Spritze
DE10193450D2 (de) Gehörschutzstöpsel
PT1178981E (pt) 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
DE60023003D1 (de) Haarbehandlungsmittel
PT1305314E (pt) Agente terapeutico cristalino
GB0030067D0 (en) Therapeutic agent
NO20016301D0 (no) Terapeutiske midler
DE50109641D1 (de) Textilbehandlungsmittel
SE0103854D0 (sv) Therapeutic agents
SE0103855D0 (sv) Therapeutic agents
DE10193217D2 (de) Therapiegerät
DK1305314T3 (da) Krystallinsk terapeutisk middel